• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Can Smoking Marijuana Reduce PTSD Symptoms?
RESEARCH UPDATE

Can Smoking Marijuana Reduce PTSD Symptoms?

September 1, 2023
Gregory Lande, MD.
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Gregory Lande, MD. Dr. Lande, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Bonn-Miller MO et al, PLoS ONE 2021;16(3):e0246990

STUDY TYPE: Randomized controlled trial

More and more veterans are using cannabis to treat their PTSD symptoms, despite the lack of high-quality safety and efficacy data and the high comorbidity between PTSD and cannabis use disorder (Bryan JL et al, J Subst Abuse Treat 2021;122:108254). Researchers hoped to fill this knowledge gap by utilizing a ­double-blind crossover design to assess three preparations of smoked cannabis for the treatment of PTSD.

The study was conducted in two stages. In Stage 1, which lasted three weeks, 80 veterans with PTSD were randomized into four groups: high THC (12% THC), high CBD (11% CBD), THC+CBD (7.9% THC and 8.1% CBD), and placebo (<0.03% THC and <0.01% CBD). For context, a recent nationwide study of cannabis dispensaries found that THC and CBD content in cannabis products can vary widely. Among smoked cannabis products from medical dispensaries, the average THC content was 19.3% (range 0%–35%) and the average CBD content was 2.0% (range <5%–40%) (Cash MC et al, PLoS ONE 2020;15(3):e1230167).

Participants received 37.8 grams of the relevant study drug with no restrictions on frequency of use. The primary outcome, change in PTSD severity, was measured with the Clinician-Administered PTSD Scale (CAPS-5). At the end of Stage 1, all four groups demonstrated an overall reduction in symptoms ranging from 8.5 to 15.2 points out of a possible 80; however, the amount of symptom reduction was not significantly different between any of the groups.

In Stage 2, the remaining participants (n=74) were re-randomized into one of three active treatment groups: high THC, high CBD, and THC+CBD. This allowed for both within-subject and between-subject comparisons. All groups again experienced symptom reduction, but this time one difference reached statistical significance: The THC+CBD group had greater symptom reduction compared to the high CBD group (16.4 vs 5.7). Adverse events (AEs) throughout were characterized as mild to moderate and were similar across placebo treatment groups. A total of 13 participants discontinued the study due to an AE. Three AEs had >10% frequency: cough (12.3%), throat irritation (11.7%), and anxiety (10.4%).

The researchers behind this study acknowledged several limitations, the most significant being the fact that few participants were cannabis naïve. In fact, participants were asked to abstain from cannabis for two weeks prior to enrolling in the trial, and many were in cannabis withdrawal by the time the study started, possibly skewing results (ie, reporting improved symptoms due to alleviation of withdrawal rather than PTSD symptoms). Patient expectation likely affected the results as well, suggested by the fact that effect sizes across all groups—even placebo—were much larger than typical PTSD medication trials.

CARLAT TAKE

Despite the hint of a signal in one treatment group, this study fails to convincingly demonstrate that cannabis is an effective treatment for PTSD. The trial’s modest size and methodological shortcomings mean that further study is still warranted, but at the moment, we would discourage the use of cannabis as a PTSD treatment.


Geriatric Psychiatry Research Update
KEYWORDS cannabis double blind ptsd
    Gregory Lande, MD.

    Suboxone vs. Vivitrol for Opioid Use Disorder: How Do you Choose?

    More from this author
    www.thecarlatreport.com
    Issue Date: September 1, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Currently Available Cannabis Products
    Cannabis Use Disorder and Withdrawal
    Medicinal Cannabis
    Can Smoking Marijuana Reduce PTSD Symptoms?
    Sublocade vs SL Buprenorphine after Release from Jail
    Internet-Based Approaches for Gambling Issues
    Computer-Based Training for CBT for Women in Residential Treatments
    Learning Objectives, Cannabis, CATR, September/October 2022
    CME Post-Test - Cannabis, CATR, September/October 2022
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.